Abstract：Objective To investigate the effect of Helicobacter pylori (Hp) eradication therapy on prognosis in children with Henoch-Schonlein purpura (HSP). Methods A total of 153 children with HSP were divided into Hp infection treatment group (n=22), Hp infection control group (n=21), and Hp infection-negative group (n=110). The Hp infection treatment group received one-week triple therapy for Hp eradication in addition to conventional treatment, while the Hp infection control group and Hp infection-negative group received conventional treatment. All patients were followed up for prognostic evaluation. Results The response rates of the Hp infection treatment, control, and negative groups were 86% (19/22), 90% (19/21) and 85% (94/110), respectively (P>0.05). The recurrence rates of HSP in the Hp infection treatment, control, and negative groups were 14% (3/22), 24% (5/21) and 31% (34/110), respectively (P>0.05). The incidence of Henoch-Schonlein purpura nephritis (HSPN) in the Hp infection-negative group (36%, 40/110) and control group (33%, 7/21) was significantly higher than that in the Hp infection treatment group (5%, 1/22) (P<0.05 for both), but no significant difference in the incidence of HSPN was found between the control and negative groups (P>0.05). Conclusions One-week triple therapy for Hp eradication may be useful to reduce the incidence of HSPN in children with HSP infected with Hp.
CAI Hua-Bo,LI Yong-Bai,ZHAO Hui et al. Prognostic analysis of children with Henoch-Schonlein purpura treated by Helicobacter pylori eradication therapy[J]. CJCP, 2014, 16(3): 234-237.
Xiong LJ, Tong Y, Wang ZL, et al. Is Helicobacter pylori infection associated with Henoch-Schonlein purpura in Chinese children-a meta-analysis[J]. World J Pediatr, 2012, 8(4): 301-308.
Ozen S, Ruperto N, Dillon ML, et al. EULAR/PReS endorsed c o n s e n s u s c r i t e n a f o r t h e c l a s s i f i c a t i o n o f c h i l d h o o d vasculitldes[J]. Ann Rheum Dis, 2006, 65(7): 936-941.
Mehri N, kambiz E, Ahmad K, et al. The efficacy of a 1-week triple therapy for eradication of Helicobacter pylori infection in children[J]. Arab J Gastroenterol, 2011, 12(1): 37-39.
Franceschi F, Sepulveda AR, Gasbarrin IA, et al. Cross-reactivity of anti-CagA antibodies with vascular wall antigengs: possible pathogenic link between Helicobacter pylori infection and atherosclerosis[J]. Circulation, 2002, 106(4): 430-434.
[13]
Lenzi C, Palazzuoli A, Giordano N, et al. H pylori infection and systemic antibodies to CagA and heat shock protein 60 in patients with coronary heart disease[J]. World J Gastroenterol, 2006, 12(48): 7815-7820.
[14]
Basso D, Plebani M, Kusters JG. Pathogenesis of Helicobacter pylori infection[J]. Helicopter, 2010, 15 suppl 1: 14-20.
[15]
Li YY, Li CR, Wang GB, et al. Investigation of the change in CD4+ T cell subset in children with Henoch-Schonlein purpura[J]. Rheumatol Int, 2011, 32(12): 3785-3792.
[16]
Shin JI, Koh H, Lee JS. Henolein-Schonlein purpura associated with helicobacter pylori infection: the pathogenic roles of IgA, C3, and cryoglobulins?[J]. Pediatr Dermatol, 2009, 26(6): 768-769.
[17]
Shin JI, Park JM, Shin YH, et al. Serum IgA/C3 ratio may be a useful marker of disease activity in severe Henoch-Schonlein nephritis[J]. Nephron Clin Pract, 2005, 101(2): c72-c78.
Li Q, Lin X, Wu Z, et al. Immuno-histochemistry analysis of Helicobacter pylori antigen in renal biopsy specimens from patients with glomerulonephritis[J]. Saudi J Kidney Dis Transpl, 2013, 24(4): 751-758.
Soler MJ, Mir M, Rodriguez E, et al. Recurrence of IgA nephropathy and Henoch-Schonlein purpura after kidney transplantion: risk factors and graft survival[J]. Transplantation Proc, 2005, 37(9): 3705-3709.
